


Peripartum Cardiomyopathy: Risks Diagnosis and Management

Selma Carlson^{1,2}, Jessica Schultz¹, Bhavadharini Ramu³, Melinda B Davis⁴ 

¹Division of Cardiology, Department of Medicine, University of Minnesota, Minneapolis, MN, USA; ²Division of Cardiology, Minneapolis VA Medical Center, Minneapolis, MN, USA; ³Division of Cardiology, Department of Medicine, Medical University of South Carolina (MUSC), Charleston, SC, USA; ⁴Division of Cardiovascular Medicine, Department of Medicine, University of Michigan, Ann Arbor, MI, USA

Correspondence: Selma Carlson, Division of Cardiology, Department of Medicine, Minneapolis VA Health Care System, Minneapolis, MN, USA, Email selma.carlson@va.gov

Abstract: Peripartum cardiomyopathy is a rare cause of heart failure that occurs during late pregnancy or in the early postpartum period. Delays in diagnosis may occur as symptoms of heart failure mimic those of normal pregnancy. The diagnosis should be considered in any pregnant or postpartum woman with symptoms concerning for heart failure. If there are clinical concerns, labs including N-terminal pro-BNP should be checked, and an echocardiogram should be ordered to assess for systolic dysfunction. Prompt medical treatment tailored for pregnancy and lactation is essential to prevent adverse events. Outcomes are variable, including complete recovery, persistent myocardial dysfunction with heart failure symptoms, arrhythmias, thromboembolic events, and/or rapid deterioration requiring mechanical circulatory support and cardiac transplantation. It is essential that care is provided as part of a multidisciplinary cardio-obstetrics team including obstetrics, cardiology, maternal fetal medicine, anesthesiology, and nursing. All women with peripartum cardiomyopathy should have close follow-up with a cardiologist, although optimal duration of medical therapy following complete recovery is unknown. Women considering a subsequent pregnancy require preconception counseling and close collaboration between obstetrics and cardiology throughout pregnancy.

Keywords: peripartum, cardiomyopathy, pregnancy, heart failure

Introduction

Peripartum cardiomyopathy (PPCM) is a rare and idiopathic form of systolic heart failure affecting childbearing women towards the end of pregnancy or in the early postpartum period.

The 2019 Heart Failure Association of the European Society of Cardiology Working Group defines PPCM as

an idiopathic cardiomyopathy presenting with heart failure secondary to left ventricular systolic dysfunction towards the end of pregnancy or in the months following delivery, where no other cause is found.¹

Echocardiography is essential for the diagnosis, and diagnostic criteria require that the left ventricular ejection fraction (LVEF) is <45%, with or without left ventricular dilatation (Figure 1).¹⁻³

In the United States, reported incidence ranges from 1 in 900 to 1 in 4000 and this number is likely increasing given the increased recognition of the disease, rise in maternal age, and increase in multifetal pregnancies due to assisted reproductive techniques.⁴⁻⁶ Incidence is four times higher in African American women than in white women, and lowest in Hispanic women.^{5,7-9} Even though less than 15% of the US population is African American, in two recent US studies African American women accounted for nearly half of PPCM cases.^{5,10} Global estimates of the incidence of PPCM vary widely throughout the world, as high as 1 in 96 deliveries in parts of Nigeria and as low as 1 in 20,000 deliveries in Japan.¹¹⁻¹³

In this article, we aim to review the data regarding the pathogenesis, typical presentation, risk factors, recommendations for diagnosis, and the management of PPCM, including counseling considerations for breastfeeding and subsequent pregnancies.

Peripartum Cardiomyopathy	
Definition: Non-ischemic cardiomyopathy with reduced left ventricular ejection fraction (LVEF < 45%)	Symptoms: Heart failure symptoms including fatigue, palpitations, shortness of breath, leg swelling
Presentation: 3 rd trimester or first 6 months of post-partum period; no pre-existing heart disease	Risk Factors: Advanced maternal age, HTN, preeclampsia, AA race, obesity, smoking
PPCM Diagnosis	
Laboratory Testing and Initial Workup: Blood test: CBC, BUN, Creatinine, electrolytes LFTs, Cardiac enzymes, BNP Thyroid-stimulating hormone Chest radiograph Electrocardiogram	Echocardiography: LVEF < 45%, Fraction shortening on M-mode < 30%, LVEDD > 2.7cm/m ²
	Cardiac MRI: As needed for clinical uncertainty May help with prognostication
PPCM Management	
During Pregnancy Use: Beta-blockers, low-molecular weight heparin, digoxin, loop diuretics, hydralazine, nitrates Avoid: Warfarin, ACE inhibitors, ARBs, Sacubitril-valsartan For cardiogenic shock, mechanical circulatory support is indicated, consider early delivery	
At Delivery Close collaboration with cardio-obstetrics team, consider hemodynamic monitoring Use caution to avoid fluid overload	
Post-partum Guideline-directed management of heart failure Anticoagulation to prevent LV thrombus (warfarin preferred post-partum) if LVEF < 35% Consider external/wearable cardioverter defibrillator Contraception counseling	

Figure 1 Presentation, risk factors, diagnosis, and management of peripartum cardiomyopathy (PPCM).

Abbreviations: LVEF, left ventricular ejection fraction; HTN, hypertension; AA, African American; CBC, complete blood cell count; BUN, blood urea nitrogen; LVEDD, left ventricular end diastolic dimension; LFTs, liver function tests; MRI, magnetic resonance imaging; ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blockers; NT-pro-BNP, N terminal pro-brain natriuretic peptide.

Pathogenesis and Presentation

The precise pathogenesis of PPCM remains unknown, with prior hypotheses related to autoimmune processes, nutritional deficiencies, and hemodynamic stress of pregnancy.^{14–17} Currently, the development of PPCM is understood with a “two-hit” model, where a vascular insult caused by hormonal effects of late pregnancy and the early postpartum period induce cardiomyopathy in patients with an underlying genetic predisposition.^{18–23} Some studies have suggested the vascular insult may be due to a prolactin-mediated oxidative stress on the myocardium.²⁴ Given the association of PPCM with pre-eclampsia, it is also thought that placental angiogenic factors could provide a shared pathophysiologic mechanism.^{25,26} Furthermore, it has been shown that certain anti-adrenergic and anti-sarcomeric protein antibodies are more common in PPCM, which could suggest an additional autoimmune mechanism for PPCM.^{27,28}

The typical clinical presentation involves typical signs and symptoms of heart failure including shortness of breath on exertion, orthopnea, paroxysmal nocturnal dyspnea, edema, and chest tightness. On physical examination, patients typically demonstrate tachypnea, tachycardia, elevated jugular venous pressure, pulmonary rales, and peripheral edema.²⁹ More severe, but uncommon presentations include serious arrhythmias, cardiac arrest, thromboembolic

complications, and cardiogenic shock.^{30,31} Between 50% and 80% of the affected women recover systolic function to a normal LVEF of $\geq 50\%$, with the majority of the recovery occurring in the first 6 months.^{32,33} Partial recovery is defined as improving LVEF by at least 10%. However, some women will have serious complications including arrhythmias, thromboembolism, and cardiogenic shock in some instances requiring mechanical support or cardiac transplantation.^{5,13,32,34} Medical management centers around standard treatment for heart failure with reduced ejection fraction, with special attention to increased risk of thromboembolism in these women, adverse effects of some medications on the fetus for women who are still pregnant, and risk of lethal arrhythmias in the postpartum period. Timing and mode of delivery should be discussed with the patient and carefully planned by a multidisciplinary cardio-obstetrics team, including obstetrics, cardiology, maternal fetal medicine, anesthesiology, and nursing.³⁵ There is risk of relapse with subsequent pregnancies, and thus close collaboration and follow-up by cardiology and obstetrics is essential even in patients who have recovered systolic function.

Risk Factors

The incidence of PPCM is higher in women of African descent. Possible reasons for this include genetic predisposition, higher incidence of pre-eclampsia in these women, and regional nutritional deficiencies; however, racial and ethnic disparities in outcomes also exist and are likely related to systemic inequities and racism.^{36,37} While PPCM occurs in approximately 1 in 100 live births in Nigeria, the rate is approximately 1 in 10,000 in Denmark and 1 in 20,000 in Japan.^{11,12,38} In the United States, several statewide studies have reported PPCM occurring 3 to 4 times as often in African American women compared with white women, and the rates are lowest in Hispanic women.^{5,7-9}

Hypertension and pre-eclampsia are strongly associated with PPCM. A meta-analysis of 22 studies of PPCM reported that pre-eclampsia was present in 22% of the women with PPCM as compared to 5% of the other pregnancies, and that other hypertensive disorders were present in 37% of the women with PPCM as compared to 13% of all pregnancies.^{39,40} The majority of women with pre-eclampsia do not develop PPCM, which requires a decreased systolic function for diagnosis. Rather, hypertension and pre-eclampsia lead to predominant diastolic dysfunction.

PPCM also appears to be associated with increasing maternal age, with one-half of cases occurring in women over 30 years of age with an adjusted odds ratio of 1.8 compared to those younger than 30 years.^{9,29} Furthermore, one study found that women over 40 years of age had an odds ratio of 10 of developing PPCM compared to women under 20 years of age.⁵ This trend is reflected in an analysis of US data that showed an incidence of 1 in 1200 of PPCM in women 20–29 years of age and 1 in 270 in women greater than 40 years of age.⁵ Multigestational pregnancies are also shown to increase the risk of PPCM with a threefold risk reported for twin gestations.⁴¹ In the United States, 7–14.5% of the women with PPCM occur in the setting of a multigestational pregnancy.⁴¹⁻⁴³

Multiple serum biomarkers have been associated with PPCM. Serum prolactin level has been shown to be significantly elevated at baseline in patients with PPCM compared to controls. While the baseline prolactin level has not been shown to be prognostic, the failure of this to decrease over time is associated with lack of PPCM recovery.⁴⁴ Similarly, the persistent elevation of markers of inflammation and oxidative stress such as oxidized low-density lipoprotein (ox-LDL) and interferon-gamma (INF-g) have also been associated with lack of recovery while elevations of C-reactive protein (CRP), white blood cell (WBC) count and monocyte to high-density lipoprotein ratio (MHR) may be predictive of persistent systolic dysfunction.^{45,46} Additionally, early post-partum serum biomarkers of vascular endothelial dysfunction have also been prognostic. Relaxin-2 is associated with greater recovery and less ventricular remodeling, while soluble Fms-like tyrosine kinase (sFlt1) is associated with disease progression and poorer prognosis.²⁶

Multiple studies have identified a genetic component to PPCM. In fact, approximately 16% of the patients report a family history of HF.⁴⁷ A study assessing 43 genes with a known association with dilated cardiomyopathy in patients with PPCM showed a positive association in 15%.²¹ Specific associated genes include a gene for the sarcomeric protein titin (TTN), a mutation near the vascular homeostasis parathyroid hormone-like hormone (PTH1H) gene, as well as the dystrophic gene.²¹ Additional genes include the beta-myosin heavy chain (MYH7), a sodium voltage-gated channel alpha subunit 5 (SCN5A), and myosin binding protein C (MYBPC3).⁴⁸ Truncating variants of the TTN gene have been shown to carry a worse prognosis in PPCM. Given our understanding, genetic testing may be a useful screening tool in patients with a family history of PPCM.⁴⁹ However, the genetic origin of PPCM is most likely

incompletely penetrant since most women do not have a family history of PPCM and do not always develop recurrent PPCM in subsequent pregnancies.³

Closer surveillance of women at high risk during pregnancy is essential as earlier detection of PPCM can lead to more appropriate treatment and safer delivery as well as postpartum care.

Diagnosis

Due to under-recognition of PPCM and the overall similarity in signs and symptoms of normal pregnancy with those of heart failure, there are frequent delays in diagnosis. PPCM is a diagnosis of exclusion, and it is essential that the patient is evaluated for possible pre-existing heart disease. Lab testing should include checking levels N-terminal pro-BNP (NT-pro BNP), which do not change significantly during pregnancy but will be markedly elevated in PPCM. The electrocardiogram is often normal but may show nonspecific abnormalities.^{50,51} An echocardiogram is essential in any suspected case of PPCM. In addition to systolic dysfunction, the echocardiogram may demonstrate left ventricular dilatation, functional mitral and/or tricuspid regurgitation, right ventricular dysfunction, pulmonary hypertension, and atrial enlargement.^{52,53} The left ventricular apex should be clearly visualized to evaluate for intracardiac thrombus. If echocardiogram is inadequate, cardiac magnetic resonance imaging should be considered for a more accurate measure of systolic function and chamber measurements.⁵⁴ Notably, gadolinium is avoided during pregnancy. If there is concern for an alternative diagnosis that would require different management, endomyocardial biopsy may be considered but is rarely needed. Further research is needed to address knowledge gaps regarding the optimal diagnostic strategy, which may include a combination of genetic testing, serum biomarkers, laboratory values, and imaging findings.

Management

Very few studies of management have been performed specifically in patients with peripartum cardiomyopathy. As a result, the treatment of PPCM is derived from a combination of expert opinion as well as recommendations for other forms of systolic heart failure. The guidelines advise that standard treatment for systolic heart failure is indicated for patients with PPCM, with special consideration for fetal safety in pregnant patients and for safety of newborns in breastfeeding mothers.^{53,55,56} The first-line therapy of volume management is dietary sodium restriction, but loop diuretics can be used safely in patients with peripheral or pulmonary edema.⁵⁷ Beta-blockers, hydralazine/nitrates, and digoxin can also be used safely during pregnancy.^{22,52,58,59} Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (ACEi/ARBs), sacubitril-valsartan, sodium glucose co-transporter 2 (SGLT2) inhibitors and mineralocorticoid receptor antagonists should be avoided during pregnancy.^{59–62} Heart failure medications that are compatible with breastfeeding include evidence based beta-blockers, certain ACEi such as captopril or enalapril and mineralocorticoid inhibitors. (Table 1)

In patients who develop acute decompensated heart failure, nitroglycerine may be necessary and is preferred to nitroprusside owing to the potential risk of cyanide toxicity in the latter. There is one study that suggested β -agonists (ie dobutamine) in patients with PPCM and severe left ventricular dysfunction (LVEF $\leq 25\%$) may be detrimental and precipitate the need for left ventricular assist device or transplantation.⁶³ However, more studies are needed. Bromocriptine is a dopamine (D2) agonist that inhibits prolactin production and is a promising drug under investigation in the REBIRTH study for treatment in women with PPCM.⁶⁴ At present, it may be reasonable in patients with cardiogenic shock or severe LV dysfunction (EF $< 25\%$).^{65–68} As it suppresses lactation, implications for breastfeeding should be discussed prior to initiation.

After delivery, cardiac medications are continued indefinitely in the presence of persistent cardiac dysfunction.²² Optimal duration of treatment is unknown after systolic recovery. However, expert opinion suggests that in low-risk patients with fully normalized myocardial function for at least a year, medications could be slowly weaned in a stepwise approach with frequent clinical assessment and echocardiographic monitoring, potentially every 3–6 months. All patients who have recovered function should continue with annual clinic assessment by a cardiologist. We discuss some special consideration in treatment and counseling of patients with PPCM below.

Table 1 Peripartum Cardiomyopathy Medications and Safety in Pregnancy and with Lactation

Medication	Indications	Adverse Effects	During Pregnancy	During Lactation
Beta blockers	Standard heart failure (HF) treatment	Intrauterine growth restriction (IUGR), fetal bradycardia, hypoglycemia	Yes	Yes
Loop diuretics	Volume management	Hypovolemia and hypotension	Yes	Yes
Vasodilators <ul style="list-style-type: none"> • Hydralazine • Nitrates 	Afterload reduction during pregnancy	Hypotension	Yes	Yes
Digoxin	Symptomatic HF treatment	None	Yes	Yes
Angiotensin-Converting Enzyme inhibitors (ACEi)/Angiotensin Receptor Blockers (ARB)	Guideline-directed medical therapy for afterload reduction	IUGR, stillbirth, pulmonary atresia, oligohydramnios, neonatal hypotension, neonatal death	No	Yes for enalapril, captopril, and benazepril
Aldosterone receptor antagonists	Guideline-directed medical therapy for HF	Antiadrenergic effects with spironolactone	No	Yes
Sacubitril-valsartan	Guideline-directed medical therapy for HF	IUGR, stillbirth, pulmonary atresia, oligohydramnios, neonatal hypotension, neonatal death	No	No data in humans
Low-molecular weight heparin	Prevention and treatment of thromboembolic complications in pregnancy, bridge to warfarin post-partum	Caution at time of delivery	Yes	Yes
Warfarin	Postpartum treatment of thromboembolic complications	Warfarin embryopathy and fetopathy	No	Yes

Anticoagulation

Pregnant women and those in the early post-partum period are at increased risk of thrombosis due to the hypercoagulable state of pregnancy.⁶⁹ Furthermore, patients with PPCM have been found to have an increased incidence of left ventricular thrombi when compared to other forms of cardiomyopathy.^{5,13,51,70} Thus, anticoagulation may be considered in the setting of severe left ventricular dysfunction in the peripartum period to 8 weeks postpartum^{53,55} Anticoagulation is also recommended in patients who receive bromocriptine, given its increased risk of thromboembolism, stroke and myocardial infarction.⁶⁰ There are no established data on whether therapeutic or prophylactic anticoagulation should be used. Unfractionated and low-molecular-weight heparin can be used during pregnancy and lactation. Warfarin should not be used during pregnancy but is safe with lactation.⁷¹ The novel anticoagulants are currently avoided as they have not been sufficiently studied during pregnancy or lactation.

Labor and Delivery

Multidisciplinary coordination by a cardio-obstetrics team of experts, including obstetrics, cardiology, maternal fetal medicine, anesthesiology, and nursing, is essential in timing and mode of delivery.^{35,72} It is recommended that hemodynamically stable patients are safe to continue pregnancy with a preference for vaginal delivery. According to American Heart Association (AHA) and European Society of Cardiology (ESC) guidelines, cesarean delivery may be considered in cases of acute heart failure, but is associated with increased risks of thromboembolism, infection, and hemorrhage.^{60,73} Invasive hemodynamic monitoring during labor and in the early post-partum period should be considered in patients with unstable hemodynamics.²²

Lactation

Most medications required for treatment of PPCM can be given safely with breastfeeding. The 2010 European Society of Cardiology statement on PPCM recommended against breastfeeding due to the postulated link between prolactin and PPCM.³ However, subsequent IPAC data have not shown breastfeeding to be associated with adverse outcomes and a small study from the United States suggests breastfeeding may be associated with a higher chance of recovery.^{24,74} Given this and the known benefits of breastfeeding to the infant, many experts recommend breastfeeding in those stable enough to do so.⁷⁵⁻⁷⁷

Sudden Death Prevention

Both cardioversion and defibrillation are safe in pregnancy and should be performed as indicated in any patient.⁷⁸ Fetal monitoring can be considered in non-emergent settings to assess for secondary fetal arrhythmias.⁷⁹ Early implantation of an ICD is usually discouraged as most patients recover to an LVEF \geq 35% within 6 months.⁶⁰ Both the AHA and ESC recommend consideration of wearable cardioverter defibrillators (WCDs) in these patients as they could also be used to bridge to an ICD in patients that do not recover.^{53,55,60,80} A recent study examining the use of WCDs in pregnancy found that arrhythmia detection remained excellent despite the altered anatomy and physiology, but since no shocks were delivered in these patients, the efficacy of these devices remains unclear.⁸¹

Contraception

Contraception should be discussed with all women with PPCM prior to discharge and should be emphasized by the patient's cardiologist and obstetrician.⁸² Estrogen-containing contraceptives should be avoided if possible in the early postpartum setting given the risk of thromboembolism in the setting of systolic dysfunction. Safe and effective choices include progesterone-releasing subcutaneous implants or the Mirena intrauterine device, with tubal ligation and vasectomy as options for those not considering future pregnancy.

Subsequent Pregnancies

Patient counseling regarding subsequent pregnancies is essential. LVEF before a subsequent pregnancy is the strongest predictor of outcomes, with substantially worse outcomes in women whose ventricular function fails to normalize (LVEF \geq 50%) (Figure 2).^{83,84} Prior to pregnancy, teratogenic heart failure medications should be discontinued for at least 3 months and systolic function reassessed to ensure it remains normal prior to determining a patient as having recovered ventricular function. Even with normalized systolic function, subsequent pregnancies carry risk of relapse and persistent




Figure 2 Subsequent pregnancy for patients with history of PPCM. The risks and recommendations vary based on the patient's LVEF recovery status. The risks are much higher in those with non-recovered PPCM (LVEF <50%) and pregnancy should be discouraged in these patients.

Abbreviations: PPCM, peripartum cardiomyopathy; LV, left ventricle; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; EF, ejection fraction; NT-pro BNP, N terminal pro-brain natriuretic peptide.

cardiac dysfunction.⁸⁴ Assessing for subclinical ventricular dysfunction with stress testing and echocardiographic strain imaging may help identify patients at higher risk for relapse.^{85–88} Although there is not enough data, prophylactic use of beta-blockers during subsequent pregnancies should be considered in women with recovered systolic function. Women should be thoroughly counseled about the risks of subsequent pregnancy. Those choosing to become pregnant should be closely monitored during pregnancy and for 6 months postpartum with serial echocardiograms and clinical exams by a cardiologist.^{22,89}

Conclusion

PPCM should be considered in any pregnant or postpartum patient with symptoms concerning for heart failure. Although uncommon, it is a serious medical condition that affects women of childbearing age throughout the world. The etiology of PPCM is not fully understood, but both genetic susceptibility and hormonal influences play major role. In patients with clinical symptoms and an elevated NT-pro-BNP level, an echocardiogram is essential for assessment of systolic function. Multidisciplinary collaboration within a cardio-obstetrics team is necessary for prompt treatment, delivery planning, and postpartum care, and may prevent adverse outcomes. Development of more specific diagnostic criteria such as specific imaging findings, serum biomarker level, and/or genetic markers could help clinicians initiate more timely treatment. Given the rarity and underdiagnosis of PPCM, research collaboration among multiple centers is needed to answer important questions and define optimal management strategies. Significant gaps in knowledge remain, including the optimal anticoagulation strategy, timing of ICD implantation, frequency of imaging as well as more precise evaluation with strain imaging and stress testing for women who recover their systolic function, management of subsequent pregnancy, and long-term medical management after myocardial recovery.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Bauersachs J, König T, van der Meer P, et al. Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. *Eur J Heart Fail.* 2019;21(7):827–843. doi:10.1002/ehfj.1493
2. Pearson GD, Veille JC, Rahimtoola S, et al. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. *JAMA.* 2000;283(9):1183–1188. doi:10.1001/jama.283.9.1183
3. Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. *Eur J Heart Fail.* 2010;12(8):767–778. doi:10.1093/eurjhf/hfq120
4. Gunderson EP, Croen LA, Chiang V, Yoshida CK, Walton D, Go AS. Epidemiology of peripartum cardiomyopathy: incidence, predictors, and outcomes. *Obstet Gynecol.* 2011;118(3):583–591. doi:10.1097/AOG.0b013e318229e6de
5. Kolte D, Khera S, Aronow WS, et al. Temporal trends in incidence and outcomes of peripartum cardiomyopathy in the United States: a nationwide population-based study. *J Am Heart Assoc.* 2014;3(3):e001056.
6. Mielniczuk LM, Williams K, Davis DR, et al. Frequency of peripartum cardiomyopathy. *Am J Cardiol.* 2006;97(12):1765–1768. doi:10.1016/j.amjcard.2006.01.039
7. Brar SS, Khan SS, Sandhu GK, et al. Incidence, mortality, and racial differences in peripartum cardiomyopathy. *Am J Cardiol.* 2007;100(2):302–304. doi:10.1016/j.amjcard.2007.02.092
8. Harper MA, Meyer RE, Berg CJ. Peripartum cardiomyopathy: population-based birth prevalence and 7-year mortality. *Obstet Gynecol.* 2012;120(5):1013–1019. doi:10.1097/AOG.0b013e31826e46a1
9. Kao DP, Hsich E, Lindenfeld J. Characteristics, adverse events, and racial differences among delivering mothers with peripartum cardiomyopathy. *JACC Heart Fail.* 2013;1(5):409–416. doi:10.1016/j.jchf.2013.04.011
10. Krishnamoorthy P, Garg J, Palaniswamy C, et al. Epidemiology and outcomes of peripartum cardiomyopathy in the United States: findings from the Nationwide Inpatient Sample. *J Cardiovasc Med.* 2016;17(10):756–761. doi:10.2459/JCM.0000000000000222
11. Karaye KM, Ishaq NA, Sa'idu H, et al. Incidence, clinical characteristics, and risk factors of peripartum cardiomyopathy in Nigeria: results from the PEACE Registry. *ESC Heart Fail.* 2020;7(1):235–243.
12. Kamiya CA, Kitakaze M, Ishibashi-Ueda H, et al. Different characteristics of peripartum cardiomyopathy between patients complicated with and without hypertensive disorders. Results from the Japanese Nationwide survey of peripartum cardiomyopathy. *Circ J.* 2011;75(8):1975–1981. doi:10.1253/circj.CJ-10-1214
13. Sliwa K, Petrie MC, van der Meer P, et al. Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry. *Eur Heart J.* 2020;41(39):3787–3797. doi:10.1093/eurheartj/ehaa455
14. Fett JD. Viral infection as a possible trigger for the development of peripartum cardiomyopathy. *Int J Gynaecol Obstet.* 2007;97(2):149–150. doi:10.1016/j.ijgo.2007.01.012

15. Fett JD, Ansari AA, Sundstrom JB, Combs GF. Peripartum cardiomyopathy: a selenium disconnection and an autoimmune connection. *Int J Cardiol.* 2002;86(2-3):311-316.
16. Ansari AA, Fett JD, Carraway RE, Mayne AE, Onlamoon N, Sundstrom JB. Autoimmune mechanisms as the basis for human peripartum cardiomyopathy. *Clin Rev Allergy Immunol.* 2002;23(3):301-324. doi:10.1385/CRAI:23:3:301
17. Lamparter S, Pankuweit S, Maisch B. Clinical and immunologic characteristics in peripartum cardiomyopathy. *Int J Cardiol.* 2007;118(1):14-20. doi:10.1016/j.ijcard.2006.04.090
18. Fett JD, Sundstrom BJ, Etta KM, Ansari AA. Mother-daughter peripartum cardiomyopathy. *Int J Cardiol.* 2002;86(2-3):331-332.
19. Pearl W. Familial occurrence of peripartum cardiomyopathy. *Am Heart J.* 1995;129(2):421-422. doi:10.1016/0002-8703(95)90032-2
20. van Spaendonck-Zwarts KY, Posafalvi A, van den Berg MP, et al. Titin gene mutations are common in families with both peripartum cardiomyopathy and dilated cardiomyopathy. *Eur Heart J.* 2014;35(32):2165-2173. doi:10.1093/eurheartj/ehu050
21. Ware JS, Li J, Mazaika E, et al. Shared genetic predisposition in peripartum and dilated cardiomyopathies. *N Engl J Med.* 2016;374(3):233-241. doi:10.1056/NEJMoa1505517
22. Davis MB, Arany Z, McNamara DM, Goland S, Elkayam U. Peripartum cardiomyopathy: JACC state-of-the-art review. *J Am Coll Cardiol.* 2020;75(2):207-221. doi:10.1016/j.jacc.2019.11.014
23. Goli R, Li J, Brandimarto J, et al. Genetic and phenotypic landscape of peripartum cardiomyopathy. *Circulation.* 2021;143(19):1852-1862. doi:10.1161/CIRCULATIONAHA.120.052395
24. Hilfiker-Kleiner D, Kaminski K, Podewski E, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. *Cell.* 2007;128(3):589-600. doi:10.1016/j.cell.2006.12.036
25. Honigberg MC, Cantonwine DE, Thomas AM, Lim KH, Parry SI, McElrath TF. Analysis of changes in maternal circulating angiogenic factors throughout pregnancy for the prediction of preeclampsia. *J Perinatol.* 2016;36(3):172-177. doi:10.1038/jp.2015.170
26. Damp J, Givertz MM, Semigran M, et al. Relaxin-2 and soluble Flt1 levels in peripartum cardiomyopathy: results of the multicenter IPAC study. *JACC Heart Fail.* 2016;4(5):380-388. doi:10.1016/j.jchf.2016.01.004
27. Haghikia A, Kaya Z, Schwab J, et al. Evidence of autoantibodies against cardiac troponin I and sarcomeric myosin in peripartum cardiomyopathy. *Basic Res Cardiol.* 2015;110(6):60. doi:10.1007/s00395-015-0517-2
28. Liu J, Wang Y, Chen M, et al. The correlation between peripartum cardiomyopathy and autoantibodies against cardiovascular receptors. *PLoS One.* 2014;9(1):e86770. doi:10.1371/journal.pone.0086770
29. Elkayam U. Clinical characteristics of peripartum cardiomyopathy in the United States: diagnosis, prognosis, and management. *J Am Coll Cardiol.* 2011;58(7):659-670. doi:10.1016/j.jacc.2011.03.047
30. Puri A, Sethi R, Singh B, et al. Peripartum cardiomyopathy presenting with ventricular tachycardia: a rare presentation. *Indian Pacing Electrophysiol J.* 2009;9(3):186-189.
31. Carlson S, Gravely A, Adabag S. Trajectory of left ventricular ejection fraction among individuals eligible for implantable cardioverter-defibrillator. *Pacing Clin Electrophysiol.* 2021;44(5):800-806. doi:10.1111/pace.14168
32. McNamara DM, Elkayam U, Alharethi R, et al. Clinical outcomes for peripartum cardiomyopathy in North America: results of the IPAC study (Investigations of Pregnancy-Associated Cardiomyopathy). *J Am Coll Cardiol.* 2015;66(8):905-914. doi:10.1016/j.jacc.2015.06.1309
33. Irizarry OC, Levine LD, Lewey J, et al. Comparison of clinical characteristics and outcomes of peripartum cardiomyopathy between African American and Non-African American Women. *JAMA Cardiol.* 2017;2(11):1256-1260. doi:10.1001/jamacardio.2017.3574
34. Sliwa K, Mebazaa A, Hilfiker-Kleiner D, et al. Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (PPCM): eURObservational research programme in conjunction with the Heart Failure Association of the European Society of Cardiology Study Group on PPCM. *Eur J Heart Fail.* 2017;19(9):1131-1141. doi:10.1002/ehf.780
35. Davis MB, Arendt K, Bello NA, et al. Team-based care of women with cardiovascular disease from pre-conception through pregnancy and postpartum. *J Am Coll Cardiol.* 2021;77(14):1763-1777. doi:10.1016/j.jacc.2021.02.033
36. Carland C, Panelli DM, Leonard SA, et al. Association of neighborhood income with clinical outcomes among pregnant patients with cardiac disease. *Reprod Sci.* 2022;29(10):3007-3014. doi:10.1007/s43032-022-00978-z
37. Olanipekun T, Abe T, Effoe V, et al. Racial and ethnic disparities in the trends and outcomes of cardiogenic shock complicating peripartum cardiomyopathy. *JAMA Network Open.* 2022;5(7):e2220937. doi:10.1001/jamanetworkopen.2022.20937
38. Ersbøll AS, Johansen M, Damm P, Rasmussen S, Vejstrup NG, Gustafsson F. Peripartum cardiomyopathy in Denmark: a retrospective, population-based study of incidence, management and outcome. *Eur J Heart Fail.* 2017;19(12):1712-1720. doi:10.1002/ehf.882
39. Creanga AA, Berg CJ, Syverson C, Seed K, Bruce FC, Callaghan WM. Pregnancy-related mortality in the United States, 2006-2010. *Obstet Gynecol.* 2015;125(1):5-12. doi:10.1097/AOG.0000000000000564
40. Ford ND, Cox S, Ko JY, et al. Hypertensive disorders in pregnancy and mortality at delivery hospitalization — United States, 2017-2019. *MMWR Morb Mortal Wkly Rep.* 2022;71(17):585-591. doi:10.15585/mmwr.mm7117a1
41. Bello N, Rendon ISH, Arany Z. The relationship between pre-eclampsia and peripartum cardiomyopathy: a systematic review and meta-analysis. *J Am Coll Cardiol.* 2013;62(18):1715-1723. doi:10.1016/j.jacc.2013.08.717
42. Amos AM, Jaber WA, Russell SD. Improved outcomes in peripartum cardiomyopathy with contemporary. *Am Heart J.* 2006;152(3):509-513. doi:10.1016/j.ahj.2006.02.008
43. Goland S, Bitar F, Modi K, et al. Evaluation of the clinical relevance of baseline left ventricular ejection fraction as a predictor of recovery or persistence of severe dysfunction in women in the United States with peripartum cardiomyopathy. *J Card Fail.* 2011;17(5):426-430. doi:10.1016/j.cardfail.2011.01.007
44. Forster O, Hilfiker-Kleiner D, Ansari AA, et al. Reversal of IFN-gamma, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy. *Eur J Heart Fail.* 2008;10(9):861-868. doi:10.1016/j.ejheart.2008.07.005
45. Ekizler FA, Cay S. A novel marker of persistent left ventricular systolic dysfunction in patients with peripartum cardiomyopathy: monocyte count-to-HDL cholesterol ratio. *BMC Cardiovasc Disord.* 2019;19(1):114. doi:10.1186/s12872-019-1100-9
46. Sanusi M, Momin ES, Mannan V, et al. Using echocardiography and biomarkers to determine prognosis in peripartum cardiomyopathy: a systematic review. *Cureus.* 2022;14(6):e26130. doi:10.7759/cureus.26130
47. Zigelbaum NK, Bhinder J, Gupta CA, Frishman WH, Aronow WS. Peripartum cardiomyopathy incidence, risk factors, diagnostic criteria, pathophysiology, and treatment options. *Cardiol Rev.* 2020;28(3):148-155.

48. Koziol KJ, Aronow WS, Giuliani E, Nunziata A. Peripartum cardiomyopathy: current understanding of pathophysiology, diagnostic workup, management, and outcomes. *Curr Probl Cardiol*. 2023;48(8):101716.
49. Morales A, Painter T, Li R, et al. Rare variant mutations in pregnancy-associated or peripartum cardiomyopathy. *Circulation*. 2010;121(20):2176–2182. doi:10.1161/CIRCULATIONAHA.109.931220
50. Honigberg MC, Elkayam U, Rajagopalan N, et al. Electrocardiographic findings in peripartum cardiomyopathy. *Clin Cardiol*. 2019;42(5):524–529. doi:10.1002/clc.23171
51. Tibazarwa K, Lee G, Mayosi B, Carrington M, Stewart S, Sliwa K. The 12-lead ECG in peripartum cardiomyopathy. *Cardiovasc J Afr*. 2012;23(6):322–329. doi:10.5830/CVJA-2012-006
52. Arany Z, Elkayam U. Peripartum Cardiomyopathy. *Circulation*. 2016;133(14):1397–1409. doi:10.1161/CIRCULATIONAHA.115.020491
53. Bozkurt B, Colvin M, Cook J, et al. Current diagnostic and treatment strategies for specific dilated cardiomyopathies: a scientific statement from the American Heart Association. *Circulation*. 2016;134(23):e579–e646. doi:10.1161/CIR.0000000000000455
54. Pierce T, Hovnanian M, Hedgire S, Ghoshhajra B. Imaging of cardiovascular disease in pregnancy and the peripartum period. *Curr Treat Options Cardiovasc Med*. 2017;19(12):94. doi:10.1007/s11936-017-0593-8
55. Bauersachs J, Arrigo M, Hilfiker-Kleiner D, et al. Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. *Eur J Heart Fail*. 2016;18(9):1096–1105. doi:10.1002/ejhf.586
56. Heidenreich PA, Bozkurt B, Aguilar D; Writing Committee Members, ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA guideline for the management of heart failure. *J Card Fail*. 2022;28(5):e1–e167. doi:10.1016/j.cardfail.2022.02.010
57. Bello NA, Bairey Herz CN, Brown H, et al. Diagnostic cardiovascular imaging and therapeutic strategies in pregnancy: JACC focus seminar 4/5. *J Am Coll Cardiol*. 2021;77(14):1813–1822. doi:10.1016/j.jacc.2021.01.056
58. Enriquez AD, Economy KE, Tedrow UB. Contemporary management of arrhythmias during pregnancy. *Circ Arrhythm Electrophysiol*. 2014;7(5):961–967. doi:10.1161/CIRCEP.114.001517
59. Halpern DG, Weinberg CR, Pinnelas R, Mehta-Lee S, Economy KE, Valente AM. Use of medication for cardiovascular disease during pregnancy. *J Am Coll Cardiol*. 2019;73(4):457–476. doi:10.1016/j.jacc.2018.10.075
60. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy. *Eur Heart J*. 2018;39(34):3165–3241. doi:10.1093/eurheartj/ehy340
61. Hanssens M, Keirse MJ, Vankelecom F, Van Assche FA. Fetal and neonatal effects of treatment with angiotensin-converting enzyme inhibitors in pregnancy. *Obstet Gynecol*. 1991;78(1):128–135.
62. Shotan A, Widerhorn J, Hurst A, Elkayam U. Risks of angiotensin-converting enzyme inhibition during pregnancy: experimental and clinical evidence, potential mechanisms, and recommendations for use. *Am J Med*. 1994;96(5):451–456. doi:10.1016/0002-9343(94)90172-4
63. Stapel B, Kohlhaas M, Ricke-Hoch M, et al. Low STAT3 expression sensitizes to toxic effects of β -adrenergic receptor stimulation in peripartum cardiomyopathy. *Eur Heart J*. 2017;38(5):349–361. doi:10.1093/eurheartj/ehw086
64. McNamara DM. Randomized Evaluation of Bromocriptine in Myocardial Recovery Therapy for Peripartum Cardiomyopathy (REBIRTH) [Internet]. clinicaltrials.gov; Report No.: NCT05180773; 2022. Available from: <https://clinicaltrials.gov/ct2/show/NCT05180773>. Accessed April 28, 2023.
65. Sliwa K, Blauwet L, Tibazarwa K, et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. *Circulation*. 2010;121(13):1465–1473. doi:10.1161/CIRCULATIONAHA.109.901496
66. Seghda TAA, Boro T, Bambara JE, et al. Prognosis of peripartum cardiomyopathy in sub-Saharan Africa (Burkina Faso South-West PPCM register). *J Cardiol Cardiovasc Med*. 2020;5(2):109–113. doi:10.29328/journal.jccm.1001096
67. Haghikia A, Podewski E, Libhaber E, et al. Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. *Basic Res Cardiol*. 2013;108(4):366. doi:10.1007/s00395-013-0366-9
68. Hilfiker-Kleiner D, Haghikia A, Berliner D, et al. Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. *Eur Heart J*. 2017;38(35):2671–2679. doi:10.1093/eurheartj/ehx355
69. Moiz B; Department of Pathology and Laboratory Medicine, the Aga Khan University Hospital, Karachi, Pakistan. A review of hemostasis in normal pregnancy and puerperium. *Natl J Health Sci*. 2017;2(3):123–127. doi:10.21089/njhs.23.0123
70. Goland S, Modi K, Bitar F, et al. Clinical profile and predictors of complications in peripartum cardiomyopathy. *J Card Fail*. 2009;15(8):645–650. doi:10.1016/j.cardfail.2009.03.008
71. Briggs GG, Freeman RK, Yaffe SJ. *Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk*. Lippincott Williams & Wilkins; 2012:1728.
72. Davis MB, Walsh MN. Cardio-Obstetrics. *Circulation*. 2019;122(2):e005417. doi:10.1161/CIRCOUTCOMES.118.005417
73. Canobbio MM, Warnes CA, Aboulhosn J, et al. Management of pregnancy in patients with complex congenital heart disease: a scientific statement for healthcare professionals from the American Heart Association. *Circulation*. 2017;135(8):e50–e87. doi:10.1161/CIR.0000000000000458
74. Koczo A, Marino A, Jayabalan A, et al. Breastfeeding, cellular immune activation, and myocardial recovery in peripartum cardiomyopathy. *JACC Basic Transl Sci*. 2019;4(3):291–300. doi:10.1016/j.jacbt.2019.01.010
75. Honigberg MC, Givertz MM. Peripartum cardiomyopathy. *BMJ*. 2019;30(364):k5287. doi:10.1136/bmj.k5287
76. Victora CG, Bahl R, Barros AJD, et al. Breastfeeding in the 21st century: epidemiology, mechanisms, and lifelong effect. *Lancet*. 2016;387(10017):475–490. doi:10.1016/S0140-6736(15)01024-7
77. Nguyen B, Jin K, Ding D, Remuzzi G. Breastfeeding and maternal cardiovascular risk factors and outcomes: a systematic review. *PLoS One*. 2017;12(11):e0187923. doi:10.1371/journal.pone.0187923
78. Jeejeebhoy FM, Zelop CM, Lipman S, et al. Cardiac arrest in pregnancy: a scientific statement from the American Heart Association. *Circulation*. 2015;132(18):1747–1773. doi:10.1161/CIR.0000000000000300
79. Honigberg MC, Givertz MM. Arrhythmias in peripartum cardiomyopathy. *Card Electrophysiol Clin*. 2015;7(2):309–317. doi:10.1016/j.ccep.2015.03.010
80. Elkayam U, Goland S, Pieper PG, Silversides CK. High-risk cardiac disease in pregnancy: part II. *J Am Coll Cardiol*. 2016;68(5):502–516. doi:10.1016/j.jacc.2016.05.050

81. Olic JJ, Stöllberger C, Schukro C, et al. Usage of the wearable cardioverter-defibrillator during pregnancy. *IJC Heart Vasc.* 2022;1(41):101066. doi:10.1016/j.ijcha.2022.101066
82. Lindley KJ, Bairey MCN, Davis MB, et al. Contraception and reproductive planning for women with cardiovascular disease. *J Am Coll Cardiol.* 2021;77(14):1823–1834. doi:10.1016/j.jacc.2021.02.025
83. Elkayam U, Tummala PP, Rao K, et al. Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy. *N Engl J Med.* 2001;344(21):1567–1571. doi:10.1056/NEJM200105243442101
84. Joseph MS, Davis MB. Counseling women with peripartum cardiomyopathy about subsequent pregnancies. *Curr Treat Options Cardio Med.* 2021;23(6):41. doi:10.1007/s11936-021-00915-4
85. Fett JD, Fristoe KL, Welsh SN. Risk of heart failure relapse in subsequent pregnancy among peripartum cardiomyopathy mothers. *Int J Gynaecol Obstet.* 2010;109(1):34–36. doi:10.1016/j.ijgo.2009.10.011
86. Barbosa MM, Freire CMV, Nascimento BR, et al. Rest left ventricular function and contractile reserve by dobutamine stress echocardiography in peripartum cardiomyopathy. *Rev Port Cardiol.* 2012;31(4):287–293. doi:10.1016/j.repc.2012.02.002
87. Yucel E, Davis EF, Scott N, Lewis GD, DeFaria YD. Exercise ventricular reserve among women with a history of peripartum cardiomyopathy. *JACC Case Rep.* 2021;3(15):1649–1653.
88. Davis MB, Rameez R, Joseph MS. Cardiac function in women with peripartum cardiomyopathy. *JACC Case Rep.* 2021;3(15):1654–1655. doi:10.1016/j.jaccas.2021.07.003
89. Elkayam U. Risk of subsequent pregnancy in women with a history of peripartum cardiomyopathy. *J Am Coll Cardiol.* 2014;64(15):1629–1636. doi:10.1016/j.jacc.2014.07.961

Journal of Multidisciplinary Healthcare

Dovepress

Publish your work in this journal

The Journal of Multidisciplinary Healthcare is an international, peer-reviewed open-access journal that aims to represent and publish research in healthcare areas delivered by practitioners of different disciplines. This includes studies and reviews conducted by multidisciplinary teams as well as research which evaluates the results or conduct of such teams or healthcare processes in general. The journal covers a very wide range of areas and welcomes submissions from practitioners at all levels, from all over the world. The manuscript management system is completely online and includes a very quick and fair peer-review system. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/journal-of-inflammation-research-journal>